THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Ivan Oransky

Transparency needed in drug researchers' finances

By Ivan Oransky
October 7, 2006

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

IN AN UNUSUAL move last month, the journal Clinical Infectious Diseases published a critique by 109 clinical researchers of an investigative report by David Willman of the Los Angeles Times. Willman had probed whether Thomas Walsh, a senior researcher at the National Institutes of Health, had manipulated a trial to give a new drug a better chance of succeeding. Willman's ... (Full article: 775 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass